Business Context and Reporting Period
This Form 8-K Current Report was filed by AbbVie Inc. on December 28, 2018, with the report date of January 4, 2019. The filing addresses corporate governance and executive compensation matters under Item 5.02.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and contractual agreements rather than financial performance.
Material Changes
- Executive Compensation Agreements: Change in control agreements with named executive officers were renewed through December 31, 2020, with no other changes to the terms.
- New Executive Appointment: AbbVie entered into a new change in control agreement with Robert A. Michael following his appointment as Senior Vice President and Chief Financial Officer.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document is strictly administrative regarding executive contracts.
Key Facts for Investor Verification
- Verify the renewal of change in control agreements for named executive officers through December 31, 2020.
- Confirm the appointment of Robert A. Michael as Senior Vice President, Chief Financial Officer.
- Note that the form of the new change in control agreement for Mr. Michael was previously filed as Exhibit 10.13 of Amendment No. 5 to the Company's Registration Statement on Form 10 (filed November 16, 2012).